Park Square is pleased to announce the placement of Doug Fambrough to the Board of Directors at Switch Therapeutics.
| less than a minute read
Switch Therapeutics Appoints Douglas Fambrough, Ph.D., to Board of Directors
Get in touch
Get in touch
Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the appointment of Douglas Fambrough, Ph.D., as an independent director to its Board.
Get in touch
Get in touch
Latest Insights
/Passle/58a5cb8db00e8110e83aa395/SearchServiceImages/2026-08-19-20-29-57-758-6a8612450e2b381c3863fcf2.jpg)
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-08-04-15-32-04-091-6a7205f4b4306b41266d92f2.jpg)
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-08-04-18-23-13-222-6a722e11663e81e26a6b2c3e.jpg)
